Abstract
Background: We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease. Methods: Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans. Results: At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively. Conclusions: This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.
Original language | English |
---|---|
Pages (from-to) | 38-42 |
Number of pages | 5 |
Journal | British Journal of Cancer |
Volume | 118 |
Issue number | 1 |
DOIs | |
Publication status | Published - 9 Jan 2018 |
Keywords
- alectinib
- ALK positive
- central nervous system
- cumulative incidence rates
- disease progression
- non-small-cell lung cancer
- phase II
- CELL LUNG-CANCER
- OPEN-LABEL
- CRIZOTINIB